Pyxis Oncology, Inc. announced a strategic portfolio prioritization, focusing its resources on advancing its lead clinical program, PYX-201. This decision follows positive preliminary Phase 1 data for PYX-201, which showed significant RECIST responses in head and neck squamous cell carcinoma (HNSCC).
As a result of this prioritization, the company has decided to suspend further clinical investment in its second clinical program, PYX-106, a fully human IgG1 monoclonal antibody targeting Siglec-15. Biosion Inc., the licensor of PYX-106, will retain rights for Greater China.
The company's current cash position is expected to fund its planned monotherapy and combination therapy trials of PYX-201 into the second half of 2026. This strategic move aims to optimize capital allocation towards the asset demonstrating the most promising clinical signal.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.